Anavex Life Sciences Corp (AVXL)

[XenaLives]

Wow - didn't see any drawings because that link just went to an index, so you might want to post screenshots of those drawings to discuss.

What I DID see was pretty interesting though. Items 1&2 were translated from the Japanese. We have JAPANESE IP coverage now.

Item #3 is for a combo with an anti-epileptic.

Title Ctr PubDate
Int.Class Appl.No Applicant Inventor
1. 2018524306 Enantiomers of tetrahydro-N, N-dimethyl-2,2-diphenyl-3- furanmethanamine ( ANAVEX 2-73) and its use in the treatment of Alzheimer's type and other injuries regulated by Sigma 1 receptor JP 30.08.2018
A61K 31/341
2017564725 ?????? ??? ?????? ???????? ???, ?????
Compound (-) - Tetrahydro-N, N-dimethyl-2,2-diphenyl-3- furanmethanamine hydrochloride ((-) - ANAVEX 2-73, (-) A2-73, (-) AE 37) , Selectivity for the sigma-1 (s 1) receptor and stronger agonist activity than the (+) enantiomer of the compound at the muscarinic M 1 acetylcholine receptor. Pharmaceutical compositions comprising the (-) - enantiomer are disclosed and methods for using the above (-) enantiomer in the treatment of disorders associated with s 1 receptors and in the treatment of Alzheimer's disease are also disclosed. Also disclosed are methods for classifying cells with respect to s receptor type using the (-) enantiomer.


2. 2018524307 Crystalline form of tetrahydro-N, N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride, a process for preparing such a form and a pharmaceutical composition thereof JP 30.08.2018
C07D 307/14
2017564733 ?????? ??? ?????? ???????? ??????, ??? ????
The polymorphic form of tetrahydro-N, N-dimethyl-2,2-diphenyl-3- furanmethanamine hydrochloride ( ANAVEX 2-73) and tetrahydro-N, N-dimethyl-2,2-diphenyl- Metabolites of amine hydrochloride ( ANAVEX 2-73) are disclosed and characterized. Compositions and methods for the treatment of Alzheimer's disease comprising polymorphic forms and metabolites of tetrahydro-N, N-dimethyl-2,2-diphenyl-3- furanmethanamine hydrochloride ( ANAVEX 2-73).


3. 20180177756 A 19-144, A2-73 AND CERTAIN ANTICHOLINESTERASE INHIBITOR COMPOSITIONS AND METHOD FOR ANTI-SEIZURE THERAPY US 28.06.2018
A61K 31/341
15571877 ANAVEX LIFE SCIENCES CORP. MISSLING U. Christopher
This invention concerns a dosage form comprising a therapeutically effective amount of A19-144 or A2-73 and a therapeutically effective amount of at least one AED. This invention further encompasses a method of treating a subject in need of such treatment comprising administering a therapeutically effective amount of A19-144 or A2-73 in conjunction with an therapeutically effective amount of an AED.


4. 20180169059 ENANTIOMERS OF A2-73, ANALOGUES, AND SIGMA AGONIST ACTIVITY US 21.06.2018
A61K 31/341
15579696 ANAVEX LIFE SCIENCES CORP. Gervais Neliat
A pharmaceutical preparation comprising {circle around (-)}A2-73 substantially free of ?A2-73. This invention further includes a method treating Alzeheimer's disease in a subject in need of such treatment by the method of administering a therapeutically effective amount of {circle around (-)}A2-73 substantially free of ?A2-73.

This invention yet further includes a method of classifying cells as to sigma receptor type by the method of exposing said cells to a detectable amount of {circle around (-)}A2-73 substantially free of ?A2-73 and determining the level of sigma receptor binding


5. 20180169060 CRYSTAL FORMS OF tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride, PROCESSES OF MAKING SUCH FORMS, AND THEIR PHARMACEUTICAL COMPOSITIONS US 21.06.2018
A61K 31/341
15579705 ANAVEX LIFE SCIENCES CORP. Linda Sharon Daintree
Polymorphic forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) and a metabolite of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) are disclosed and characterized. Compositions and method for treatment of Alzheimer's disease that includes the polymorphic forms and metabolite of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73).


6. 3324956 ENANTIOMERS OF TETRAHYDRO-N,N-DIMETHYL-2,2-DIPHENYL-3-FURANMETHANAMINE (ANAVEX2-73) AND USE THEREOF IN THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER DISORDERS MODULATED BY THE SIGMA 1 RECEPTOR EP 30.05.2018
A61K 31/341
16827322 ANAVEX LIFE SCIENCES CORP NELIAT GERVAIS
The compound (-)-tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride ((-)-ANAVEX2-73, (-)A2-73, (-)AE 37) has been found to exhibit selectivity for sigma-1 (s1) receptors and stronger agonist activity at the muscarinic M1 acetylcholine receptor than the (+) enantiomer of said compound. Pharmaceutical compositions comprising the (-) enantiomer are disclosed, as are methods of using said (-) enantiomer in the treatment of disorders associated with sigma-1 receptors and the treatment of Alzheimer's disease. Methods of classifying cells with regards to sigma receptor type using the (-) enantiomer are also disclosed.

7. 3325456 CRYSTAL FORMS OF TETRA-HYDRO-N, N-DIMETHYL-2, 2-DIPHENYL-3-FURANMETHANAMINE HYDROCHLORIDE, PROCESSES FOR MAKING SUCH FORMS, AND THEIR PHARMACEUTICAL COMPOSITIONS EP 30.05.2018
C07D 307/14
16827324 ANAVEX LIFE SCIENCES CORP YORK PETER
Polymorphic forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3- furanmethanamine hydrochloride (ANAVEX2-73) and a metabolite of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) are disclosed and characterized. Compositions and method for treatment of Alzheimer's disease that includes the polymorphic forms and metabolite of tetrahydro-N,N-dimethyl-2,2- diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73).

8. 107708687 Enantiomers Of Tetrahydro-N,N-Dimethyl-2,2-Diphenyl-3-Furanmethanamine (Anavex2-73) And Use Thereof In The Treatment Of Alzheimer's Disease And Other Disorders Modulated By The Sigma 1 Receptor CN 16.02.2018
A61K 31/341
201680033151.4 ANAVEX LIFE SCIENCES CORP NELIAT GERVAIS
The compound (-)-tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride ((-)-ANAVEX2-73, (-)A2-73, (-)AE 37) has been found to exhibit selectivity for sigma-1 (sigma1) receptors and stronger agonist activity at the muscarinic M1 acetylcholine receptor than the (+) enantiomer of said compound. Pharmaceutical compositions comprising the (-) enantiomer are disclosed, as are methods ofusing said (-) enantiomer in the treatment of disorders associated with sigma-1 receptors and the treatment of Alzheimer's disease. Methods of classifying cells with regards to sigma receptor type using the (-) enantiomer are also disclosed.

9. WO/2018/022848 A2-73 AS A THERAPEUTIC FOR INSOMNIA, ANXIETY, AND AGITATION WO 01.02.2018
A61K 31/341
PCT/US2017/044111 ANAVEX LIFE SCIENCES CORP. MISSLING, Christopher
A2-73 is a useful therapeutic in the treatment of humans suffering from insomnia, anxiety or agitation. Particular attention is made to oral daily doses of from about 10mg to about 50mg, with particular reference to about 20 to 30mg.

10. 20170360798 ANAVEX2-73 AND CERTAIN ANTICHOLINESTERASE INHIBITORS COMPOSITION AND METHOD FOR NEUROPROTECTION US 21.12.2017
A61K 31/55
15695170 Anavex Life Sciences Corp. Alexandre Vamvakides
This invention concerns a dosage form comprising a therapeutically neuroprotective amount of A2-73 and a neuroprotective amount of at least one cooperating acetylcholinesterase inhibitor selected from the group consisting of donepezil, galantamine, rivastigmine, or memantine and method of use.